Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

July 21, 2019

Study Completion Date

July 21, 2019

Conditions

Chronic Kidney DiseaseChronic Kidney Disease, Stage 3 (Moderate)Chronic Kidney Disease, Stage 4 (Severe)Diabetes

Interventions

DRUG

DM199

Single SC dose

Trial Locations (3)

Orlando Clinical Research Center Inc, Orlando

Clinical Pharmacology of Miami, Hialeah

Prism Research, Saint Paul